Showing Latest Articles
Neuroimaging to assess safety and efficacy of AD therapies
Expert Opinion on Investigational Drugs, 12/09/2009
Hill D – The North American Alzheimer's Disease Neuroimaging Initiative, and similar activities in Europe, Japan, and Australia, are natural history studies that are providing new insights into the use of imaging end points in clinical trials. While the results of these trials are not yet all available, a recipe for successful deployment of imaging to assess eligibility, safety and efficacy is emerging.
